13-cis retinoic acid and interferon alfa-2a in the treatment of metastatic renal cell carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 17, Issue 2, 1998, Pages 227-229

  Casali, A ^a   Sega, F M ^a   Casali, M ^a   Serrone, L ^a   Terzoli, E ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

13 cis retinoic acid; Interferon alfa; Renal carcinoma

Indexed keywords

ALPHA2A INTERFERON; RETINOIC ACID;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; INTERFERON ALFA-2A; ISOTRETINOIN; KIDNEY NEOPLASMS; MIDDLE AGED;

EID: 0031865713     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Murray Law T., Motzer R.J., Minasian L.M., et al.: Risck stratificatio in advanced renal cell carcinoma (RCC): A single istitutionstudy of 237 patients, proc. Am. Soc. Clin. Oncol. 12: 243, 1994.
2. Minasian L.M., Motzer R.J., Cluck L., et al.: Interferon alpha 2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11: 1368-1375, 1993.
3. Ilson D.H., Motzer R.J., Kradin R.L., et al.: A phase II trial of interleukine-2 and interferon alpha-2a in patients with advanced renal cell carcinoma. J. Cell. Oncol. 10: 1124-1130, 1992.
4. Gudas L.J.: Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth Differ 3:655-662, 1992.
5. Smith M.A., Parkinson D.P., Cheson B.D., et al.: Retinoids in cancer therapy. J Clin. Oncol. 10:839-864, 1992.
6. Marth C., Daxenbichler G., Dapunt O.: Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in culture breast cancer cells. J. Natl. Cancer Inst 77:1197-1202, 1986.
7. Frey J.R., Peck R., Bollag W.: Antiproliferative activity of retinoids, interferon alpha and their combination in 5 human transformed cell lines. Cancer Lett 57:223-227, 1991.
8. Hong W.K., Lippman S.M., Itri L.M.: Prevention of second primary tumors with istotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323:795-801, 1990.
9. Warrel R.P., Jr., Frankel S.R., Miller W.H. Jr., et al.: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324:1385-1393, 1991.
10. Lippman S.M., Parkinson D.R., Itri L.M., et al.: 13-cis-retinoic acid and interferon alpha 2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J. Natl. Cancer Inst 84: 235-241, 1992.
11. Lippman S.M., Kavanagh J.J., Paredes-Espinoza M., et al.: 13-cis-retinoic acid plus interferon alpha 2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J. natl. Cancer. Inst. 84:241-245, 1992.